Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an…
xB3
Bioasis Technologies (BTI.V) announces today that the Japanese Patent Office (JPO) has issued Japanese Patent No.2019-189551 Notice of Allowance for the Company’s xB3™-IDS fusion proteins. “We are excited about…